Eyal C. Attar - Net Worth and Insider Trading
Eyal C. Attar Net Worth
The estimated net worth of Eyal C. Attar is at least $86,798 dollars as of 2024-12-01. Eyal C. Attar is the CHIEF MEDICAL OFFICER of Vor Biopharma Inc and owns about 96,063 shares of Vor Biopharma Inc (VOR) stock worth over $79,934. Eyal C. Attar is also the SVP, Chief Medical Officer of Aprea Therapeutics Inc and owns about 2,367 shares of Aprea Therapeutics Inc (APRE) stock worth over $6,864. Details can be seen in Eyal C. Attar's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Eyal C. Attar has not made any transactions after 2024-06-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Eyal C. Attar
Eyal C. Attar Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Eyal C. Attar owns 2 companies in total, including Aprea Therapeutics Inc (APRE) , and Vor Biopharma Inc (VOR) .
Click here to see the complete history of Eyal C. Attar’s form 4 insider trades.
Insider Ownership Summary of Eyal C. Attar
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| APRE | Aprea Therapeutics Inc | 2022-02-28 | SVP & Chief Medical Officer |
| VOR | Vor Biopharma Inc | 2024-06-03 | Chief Medical Officer |
Eyal C. Attar Latest Holdings Summary
Eyal C. Attar currently owns a total of 2 stocks. Among these stocks, Eyal C. Attar owns 96,063 shares of Vor Biopharma Inc (VOR) as of June 3, 2024, with a value of $79,934 and a weighting of 92.09%. Eyal C. Attar also owns 2,367 shares of Aprea Therapeutics Inc (APRE) as of February 28, 2022, with a value of $6,864 and a weighting of 7.91%.
Latest Holdings of Eyal C. Attar
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VOR | Vor Biopharma Inc | 2024-06-03 | 96,063 | 0.83 | 79,934 |
| APRE | Aprea Therapeutics Inc | 2022-02-28 | 2,367 | 2.90 | 6,864 |
Holding Weightings of Eyal C. Attar
Eyal C. Attar Form 4 Trading Tracker
According to the SEC Form 4 filings, Eyal C. Attar has made a total of 1 transactions in Vor Biopharma Inc (VOR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Vor Biopharma Inc is the sale of 14,645 shares on June 3, 2024, which brought Eyal C. Attar around $20,357.
According to the SEC Form 4 filings, Eyal C. Attar has made a total of 2 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Aprea Therapeutics Inc is the sale of 1,800 shares on February 28, 2022, which brought Eyal C. Attar around $62,280.
Insider Trading History of Eyal C. Attar
- 1
Eyal C. Attar Trading Performance
GuruFocus tracks the stock performance after each of Eyal C. Attar's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eyal C. Attar is 115.11%. GuruFocus also compares Eyal C. Attar's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eyal C. Attar within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Eyal C. Attar's insider trading performs compared to the benchmark.
Performance of Eyal C. Attar
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 19.41 | | | | | |
| Relative Return to S&P 500(%) | 14.43 | | | | | |
Eyal C. Attar Ownership Network
Eyal C. Attar Owned Company Details
What does Aprea Therapeutics Inc do?
Who are the key executives at Aprea Therapeutics Inc?
Eyal C. Attar is the SVP & Chief Medical Officer of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .
Aprea Therapeutics Inc (APRE) Insider Trades Summary
Over the past 18 months, Eyal C. Attar made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 3,900 shares made by Oren Gilad , a net purchase of 26,957 shares made by Bernd R. Seizinger , and a net purchase of 23,728 shares made by Marc Duey .
In summary, during the past 3 months, insiders sold 6,462 shares of Aprea Therapeutics Inc (APRE) in total and bought 42,590 shares, with a net purchase of 36,128 shares. During the past 18 months, 6,462 shares of Aprea Therapeutics Inc (APRE) were sold and 69,417 shares were bought by its insiders, resulting in a net purchase of 62,955 shares.
Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aprea Therapeutics Inc Insider Transactions
Eyal C. Attar Mailing Address
Above is the net worth, insider trading, and ownership report for Eyal C. Attar. You might contact Eyal C. Attar via mailing address: 535 Boylston Street, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
